When Does the Clock Start? Supreme Court Redefines Limitation in Drug Misbranding Probes

In a significant ruling for regulatory enforcers, the Supreme Court of India , led by Justices Ahsanudddin Amanullah and S.V.N. Bhatti, set aside Kerala High Court orders quashing criminal proceedings against vaccine maker Panacea Biotec Ltd. and directors of syringe firm Veekay Surgicals Pvt. Ltd. The bench clarified that time bars under the CrPC don't tick from the first whisper of wrongdoing but from when investigators pinpoint all culprits—protecting probes into complex supply chains.

From a Father's Alarm to a National Probe: The Vaccine Label Nightmare

It all began in October 2005 when Joy Mandi, alerted by a Thrissur Primary Health Centre doctor, spotted a chilling mismatch on a vaccine bought for his child. The outer carton screamed Easy Five Pentavalent Vaccine —promising protection against five diseases, including hepatitis—while the inner vial whispered Easy Four Tetravalent , missing the hepatitis component and bearing different batch dates. Priced higher on the box (Rs 550 vs Rs 500), this wasn't just sloppy packaging; it screamed misbranding under Sections 17(b), 17(c), and 18(a)(i) of the Drugs and Cosmetics Act, 1940 , punishable by up to two years' jail under Section 27(d) .

The Drugs Inspector (Intelligence Branch), Thrissur —a public servant authorized under Section 32 —sprang into action post-Mandi's January 2006 letter. No purchase bill? No problem. Inspections rippled through Kerala sellers Meenakshi Medical Agencies and others, seizing invoices and statements admitting labeling defects. By April 18, 2006 , the full supply chain—from Panacea Biotec in Delhi to local distributors—was mapped. But the formal complaint hit Thrissur's Chief Judicial Magistrate only on January 20, 2009 , leading to summons after condoning delay.

A parallel saga unfolded in Kozhikode: Inspector sampled "substandard" syringes from a health center in 2014 . Government analyst confirmed failures in sterility and extraneous matter tests by January 2016 . Complaint against Veekay Surgicals and directors followed in June 2016 .

Kerala High Court quashed both, citing expired three-year limitation under CrPC Section 468(2)(c) and mandatory pre-summons inquiry under Section 202 for out-of-jurisdiction accused.

Prosecution's Pushback: 'Public Servants Deserve Wiggle Room'

Kerala State and Drugs Inspectors argued the delay was kosher—limitation ignited only on April 18, 2006 , when all accused identities surfaced via diligent probe ( CrPC Section 469(1)(c) ). Filing by early 2009? Well within bounds, expiring April 17, 2009 . They leaned on Cheminova India Ltd. v. State of Punjab (2021) : public servant complaints skip oath exams under Section 200 proviso , placing them " on a different pedestal " to shield innocents without hamstringing public interest cases like drug safety.

Vicarious liability under Act Section 34 ? Every company honcho in charge at the time is presumptively culpable for misbranding endangering kids. No prejudice to Delhi-based firms; gravity demanded trial.

Defense Strikes Back: 'Mandatory Safeguards Ignored'

Panacea Biotec and Veekay directors countered: Post-2005 CrPC amendment, Section 202 is ironclad for distant accused—no public servant carve-out. No pre-summons inquiry? Process fatally flawed. Limitation? Starts from 2005/2006 knowledge of offence, not offender ID. Cheminova? Distinguishable—no analyst report here, just unverified labels from a complainant sans bill. Section 34 needed specifics on directors' roles, not bald claims.

Court's Sharp Scalpel: Identity Trumps Initial Tip-Off

The apex court sliced through, affirming Section 469(1)(c) defers limitation until "the first day on which the identity of the offender is known... to the police officer making investigation." Mandi's tip sparked verification; full accused roster emerged April 18, 2006 . "The Competent Authority was required to file a proper complaint before the Court, which was... done only on 20.01.2009... within the 3-year period."

On jurisdiction, harmonizing Sections 200 and 202: Public servants filing officially dodge complainant exams, so no mandatory inquiry if it harasses without cause. Echoing Cheminova: "The legislature... placed the public servant on a different pedestal ... Object [of Section 202 ] is to ensure that innocents are not harassed unnecessarily."

For syringes, Section 34 culpability? Trial court's call—directors were in management; facts will tell.

As LiveLaw ( 2026 LiveLaw (SC) 206 ) noted, this rebukes High Court linkage of limitation to "initial complaint," vital for regulatory hunts where offenders hide in chains.

Key Observations

"The period of limitation... shall commence... where it is not known by whom the offence was committed, the first day on which the identity of the offender is known to the person aggrieved... or to the police officer making investigation into the offence, whichever is earlier." (Para 33, quoting CrPC Section 469(1)(c) )

"The legislature in its wisdom has itself placed the public servant on a different pedestal , as would be evident from a perusal of proviso to Section 200 of the Code of Criminal Procedure ." (Para 40, quoting Cheminova India Limited v. State of Punjab)

"Though there is an inordinate delay... the said exercise was completed within the 3-year period... Therefore, in our view, the limitation bar does not come in the way." (Para 36)

Fresh Summons, Open Trial: Ripple Effects for Pharma Watchdogs

Impugned orders overturned. CJM's summons revived; fresh ones for substituted company heads (original MD deceased). Syringe case reinstated too. No merits prejudged—trial courts rule on facts.

This bolsters Drugs Inspectors nationwide: Deeper probes won't auto-expire cases; public duty trumps procedural nitpicks. Pharma firms face stricter scrutiny on labels saving lives, but with due process intact. A balanced win for consumer safety in India's vaccine vanguard.